8-K: Tyra Biosciences Q3 2025: Clinical Progress & Cash Runway

Tyra Biosciences reported third-quarter 2025 financial results, highlighting clinical advancements for dabogratinib and a cash runway extending through at least 2027.

Summary

• Dosed first patients with dabogratinib in BEACH301 (pediatric achondroplasia) and SURF302 (low-grade intermediate risk non-muscle invasive bladder cancer, IR NMIBC).
• Interim results from the BEACH301 safety sentinel cohort are expected in 2H 2026.
• Initial three-month complete response data from SURF302 are expected in 1H 2026.
• Expanded dabogratinib development into low-grade upper tract urothelial carcinoma (LG-UTUC) with an Investigational New Drug (IND) application cleared by the U.S. FDA; a Phase 2 study (SURF303) is expected to initiate in 2026.
• Cash, cash equivalents, and marketable securities totaled $274.9 million as of September 30, 2025.
• The current cash, cash equivalents, and marketable securities are expected to provide a runway through at least 2027.
• Research and Development (R&D) expenses for Q3 2025 were $25.5 million, an increase from $22.7 million for the same period in 2024.
• General and Administrative (G&A) expenses for Q3 2025 were $7.5 million, an increase from $5.9 million for the same period in 2024.
• Net loss for Q3 2025 was $29.9 million, compared to $24.0 million for the same period in 2024.
• TYRA-430 (for hepatocellular carcinoma, HCC) and TYRA-200 (for intrahepatic cholangiocarcinoma, ICC) studies continue to enroll and dose patients.

Sentiment

Score: 7

Explanation: The company is demonstrating steady clinical progress by dosing patients in key trials and expanding its pipeline into new indications. A strong cash position provides a runway through at least 2027, which is positive for a clinical-stage biotech. However, the increased net loss and the fact that significant interim data readouts are still several quarters away temper the immediate enthusiasm.

Positives

• Dosed first patients in two key Phase 2 studies, BEACH301 for pediatric achondroplasia and SURF302 for IR NMIBC.
• Expanded dabogratinib development into a new indication, LG-UTUC, with IND cleared by the FDA, addressing a condition where FGFR3 alterations occur in approximately 85% of cases.
• Maintained a strong cash position of $274.9 million as of September 30, 2025, providing a projected cash runway through at least 2027.
• Dabogratinib previously demonstrated encouraging anti-tumor activity and was generally well-tolerated in metastatic urothelial cancer (mUC).
• Dabogratinib has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for the treatment of achondroplasia.

Negatives

• Net loss increased to $29.9 million for Q3 2025, up from $24.0 million for Q3 2024.
• Research and Development (R&D) expenses increased to $25.5 million for Q3 2025, compared to $22.7 million for Q3 2024, primarily due to start-up and enrollment activities for BEACH301, SURF302, and SURF431.
• General and Administrative (G&A) expenses increased to $7.5 million for Q3 2025, compared to $5.9 million for Q3 2024, primarily driven by higher personnel-related costs, including non-cash stock-based compensation.
• Key interim clinical results for BEACH301 and SURF302 are not expected until 1H 2026 and 2H 2026, respectively, indicating a continued period of investment before significant data readouts.

Risks

• Interim results of a clinical trial are not necessarily indicative of final results and one or more clinical outcomes may materially change as patient enrollment continues, following more comprehensive data reviews, and as more patient or final data becomes available.
• Unconfirmed responses in clinical trials may not ultimately result in confirmed responses to treatment after follow-up evaluations.
• The potential for proof-of-concept results to fail to result in successful subsequent development of dabogratinib.
• Later developments with the FDA may be inconsistent with prior feedback from the FDA.
• The company is early in its development efforts, and the approach taken to discover and develop drugs based on its SNP platform is novel and unproven, and it may never lead to product candidates that are successful in clinical development or approved products of commercial value.
• Potential delays in the commencement, recruitment, enrollment, data readouts, and completion of preclinical studies and clinical trials.
• Results from preclinical studies or early clinical trials are not necessarily predictive of future results.
• Dependence on third parties in connection with manufacturing, research, and preclinical testing.
• Risk of expending limited resources to pursue a particular product candidate and/or indication and failing to capitalize on product candidates or indications with greater development or commercial potential.
• Acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of product candidates is not guaranteed.
• An accelerated development or approval pathway may not be available for dabogratinib or other product candidates, and any such pathway may not lead to a faster development process.
• Unexpected adverse side effects or inadequate efficacy of product candidates that may limit their development, regulatory approval, and/or commercialization.
• The potential for programs and prospects to be negatively impacted by developments relating to competitors, including the results of studies or regulatory determinations relating to competitors.
• Unfavorable results from preclinical studies.
• Regulatory developments in the United States and foreign countries.
• Ability to obtain and maintain intellectual property protection for product candidates and proprietary technologies.
• Capital resources may be used sooner than expected.
• Unstable market and economic conditions and changes in healthcare legislation, tariffs, and trade policies may adversely affect the business and financial condition and the broader economy and biotechnology industry.

Future Outlook

The company anticipates 2026 will be a pivotal year, with expected interim Phase 2 results for dabogratinib across achondroplasia, IR-NMIBC, and LG-UTUC, which could validate its broad potential. The Phase 2 SURF303 study for LG-UTUC is expected to initiate in 2026. The current cash, cash equivalents, and marketable securities are projected to fund operations through at least 2027.

Management Comments

• "Our focus remains on patients – those living with skeletal dysplasia and bladder cancer who need improved, precise options of care."
• "Enrollment continues to progress across our BEACH301 and SURF302 Phase 2 studies, reflecting strong engagement from the clinical and patient communities."
• "We are also expanding the Phase 2 development of dabogratinib into low-grade upper tract urothelial carcinoma, where FGFR3 alterations occur in approximately 85% of LG-UTUC cases, further reinforcing our commitment to addressing FGFR3-driven disorders."
• "We believe 2026 will be a pivotal year for TYRA. We expect to report interim Phase 2 results that could validate dabogratinib's broad potential across achondroplasia, IR-NMIBC and LG-UTUC."
• "We believe TYRA-430 has the potential to address a significant unmet need in HCC, where there are no approved biomarker-driven, targeted therapies."

Industry Context

Tyra Biosciences operates within the highly competitive clinical-stage biotechnology industry, specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The expansion of dabogratinib into LG-UTUC, a condition with high FGFR3 alteration prevalence, aligns with the broader industry trend of developing targeted therapies for genetically defined patient populations. The company's in-house SNP platform aims to address acquired resistance, a critical challenge in oncology drug development, positioning it within the innovative segment of the biotech sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks or industry standards.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if clinical trials are successful, but also inherent risks associated with increased operational burn rate and reliance on future clinical data.
• Patients: Potential for new, precise treatment options for achondroplasia, bladder cancer, and other FGFR-driven cancers, addressing significant unmet medical needs.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline and expands its clinical programs.
• Creditors/Suppliers: A stable financial position with a projected long cash runway reduces immediate financial risk for these stakeholders.

Next Steps

• Report initial three-month complete response data from the SURF302 study in 1H 2026.
• Initiate the Phase 2 SURF303 study for LG-UTUC in 2026.
• Report initial results from the safety sentinel cohort of the BEACH301 study in 2H 2026.
• Continue enrollment and dosing for the SURF431 study (TYRA-430 for HCC) and the SURF201 study (TYRA-200 for ICC).
• Continue evaluation of dabogratinib in Part B of SURF301 to determine an optimal dose for metastatic urothelial cancer (mUC).

Key Dates

Recommendation

Tyra Biosciences is executing on its clinical development plan, advancing multiple programs, and strategically expanding into new indications like LG-UTUC. The company's cash runway through at least 2027 provides financial stability for ongoing operations. However, the increased net loss reflects the high burn rate typical of a clinical-stage biotech, and key efficacy data readouts are still several quarters away (1H/2H 2026). Given the progress is largely as expected and significant catalysts are not immediate, a 'hold' recommendation is appropriate, awaiting more definitive clinical trial results to re-evaluate the investment thesis.

Keywords

Tyra Biosciences, TYRA, biotechnology, clinical-stage, precision medicine, FGFR biology, dabogratinib, TYRA-300, achondroplasia, BEACH301, NMIBC, SURF302, urothelial carcinoma, LG-UTUC, SURF303, oncology, hepatocellular carcinoma, HCC, TYRA-430, SURF431, cholangiocarcinoma, ICC, TYRA-200, SURF201, Q3 2025 financial results, drug development, clinical trials, Orphan Drug Designation, Rare Pediatric Disease Designation